December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

18.73 USD +3.87 (+26.04%)
Official Closing Price Updated: 7:59 PM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease 
From Business Wire News Releases
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019 
From Business Wire News Releases
Aurinia Closes At-The-Market Facility
Aurinia Closes At-The-Market Facility 
From Business Wire News Releases
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has... 
From Business Wire News Releases
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink... 
From Business Wire News Releases
Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Eco
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Leidos Holdings, Inc.... 
From GlobeNewswire News Releases
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2... 
From Business Wire News Releases
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of... 
From Business Wire News Releases
Thinking about buying stock in Aurinia Pharmaceuticals Inc, Eagle Bancorp, Canada Goose Holdings Inc., New Age Beverages Corp, or vTv Therapeutics Inc.?
InvestorsObserver issues critical PriceWatch Alerts for AUPH, EBMT, GOOS, NBEV, and VTVT. 
From PR Newswire
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P. Morgan... 
From Business Wire News Releases
Aurinia Establishes at-the-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced that it has entered into an Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC... 
From Business Wire News Releases
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abeona Therapeutics Inc.... 
From GlobeNewswire News Releases
Aurinia to Participate in November Investor Conferences
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences. 
From Business Wire News Releases
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the third quarter ended September 30, 2018. Amounts, unless specified otherwise,... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH) (TSX:AUP) today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018, after the market closes. Aurinia’s... 
From Business Wire News Releases
New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS — Factors of Influence, Major In
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Haverty Furniture... 
From GlobeNewswire News Releases
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA... 
From Business Wire News Releases
Aurinia to Participate in Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences. 
From Business Wire News Releases
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.... 
From Business Wire News Releases
Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals — Discovering Underlying Factors
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natural Resource Partners... 
From GlobeNewswire News Releases
Aurinia Reports Second Quarter Financial Results and Operational Highlights
Aurinia Reports Second Quarter Financial Results and Operational Highlights 
From Business Wire News Releases
Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its second quarter 2018 financial results on Thursday, August 9, 2018, after the market closes. Aurinia’s... 
From Business Wire News Releases
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating... 
From Business Wire News Releases
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the... 
From Business Wire News Releases
Aurinia Announces Results of Annual General Meeting
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general... 
From Business Wire News Releases
Factors of Influence in 2018, Key Indicators and Opportunity within Shinhan Financial Group, Aurinia Pharmaceuticals, Delphi Technologies, Green Plains Partners LP, Sprague Resources LP, and CRH — New
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shinhan Financial Group Co... 
From GlobeNewswire News Releases
Aurinia Reports First Quarter Financial Results and Operational Highlights
AURINIA REPORTS FIRST QUARTER FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS 
From Business Wire News Releases
Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus DayTM with activities... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its first quarter 2018 financial results on Thursday, May 10, 2018, after the market closes. Aurinia’s... 
From Business Wire News Releases
Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare Investor... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.